This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Filipits, M. Articles by Brambilla, E. Search for Related Content PubMed PubMed Citation Articles by Filipits, M. Articles by Brambilla, E. Related Articles Related Editorial Social Bookmarking                            What's this?

Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non–Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program

Martin Filipits, Robert Pirker, Ariane Dunant, Sylvie Lantuejoul, Katharina Schmid, Anh Huynh, Vincent Haddad, Fabrice André, Rolf Stahel, Jean-Pierre Pignon, Jean-Charles Soria, Helmut H. Popper, Thierry Le Chevalier, Elisabeth Brambilla

From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland

Address reprint requests to Martin Filipits, PhD, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria; e-mail: martin.filipits{at}meduniwien.ac.at

Purpose The International Adjuvant Lung Cancer Trial (IALT) demonstrated that adjuvant cisplatin-based chemotherapy improves the survival of patients with completely resected non–small-cell lung cancer (NSCLC). The purpose of our study was to determine whether cell cycle regulators are of prognostic and/or predictive value in patients who were enrolled onto the IALT.

Patients and Methods Expression of p27^Kip1, p16^INK4A, cyclin D1, cyclin D3, cyclin E, and Ki-67 was immunohistochemically assessed in tumor specimens obtained from 778 IALT patients. Prognostic and predictive analyses were based on Cox models adjusted for clinical and pathologic parameters.

Results There was a relationship between p27^Kip1 status and benefit of cisplatin-based chemotherapy (test for interaction, P = .02). Among patients with p27^Kip1-negative tumors, cisplatin-based chemotherapy resulted in longer overall survival compared with controls (adjusted hazard ratio [HR] for death = 0.66; 95% CI, 0.50 to 0.88; P = .006). In patients with p27^Kip1-positive tumors, overall survival was not different between patients treated with cisplatin-based chemotherapy and controls (adjusted HR for death = 1.09; 95% CI, 0.82 to 1.45; P = .54). The other cell cycle regulators and Ki-67 did not predict benefit of adjuvant cisplatin-based chemotherapy. None of these biomarkers was significantly associated with overall survival of the patients in the total study population.

Conclusion NSCLC patients with p27^Kip1-negative tumors benefit from adjuvant cisplatin-based chemotherapy after complete tumor resection. Before establishing p27^Kip1 as a routine marker for selection of patients for adjuvant chemotherapy, the predictive value of p27^Kip1 has to be confirmed in patients from other trials.

Supported by the Austrian Federal Ministry of Education, Science and Culture (Grant No. GZ 200.062/2-VI/1/2002), the Austrian Science Fund (Grant No. P15377), Programme Hospitalier de Recherche Clinique, Cancéropôle Rhône-Alpes, Institute of Pathology Graz, and an unrestricted research grant from Eli-Lilly.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• ERCC1-Tailored Chemotherapy in Lung Cancer: The First Prospective Randomized Trial
  Jean-Charles Soria
  JCO 2007 25: 2648-2649 [Full Text]

This article has been cited by other articles:

				J-P. Sculier and D. Moro-Sibilot First- and second-line therapy for advanced nonsmall cell lung cancer Eur. Respir. J., April 1, 2009; 33(4): 915 - 930. [Abstract] [Full Text] [PDF]

				B. Besse and T. Le Chevalier Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Fading Effect? J. Clin. Oncol., November 1, 2008; 26(31): 5014 - 5017. [Full Text] [PDF]

				J.-P. Pignon, H. Tribodet, G. V. Scagliotti, J.-Y. Douillard, F. A. Shepherd, R. J. Stephens, A. Dunant, V. Torri, R. Rosell, L. Seymour, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group J. Clin. Oncol., July 20, 2008; 26(21): 3552 - 3559. [Abstract] [Full Text] [PDF]

				D. Moro-Sibilot, S. Lantuejoul, S. Diab, N. Moulai, A. Aubert, J. F. Timsit, C. Brambilla, P. Y. Brichon, and E. Brambilla Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis Eur. Respir. J., April 1, 2008; 31(4): 854 - 859. [Abstract] [Full Text] [PDF]